Evidence map›Paper›PMID 34853898›Full record

ArticleNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2022

Validation of the DYALS (dysphagia in amyotrophic lateral sclerosis) questionnaire for the evaluation of dysphagia in ALS patients.

Luca Diamanti, Paola Borrelli, Raffaele Dubbioso, Margherita Capasso, Claudia Morelli, Christian Lunetta, Antonio Petrucci, Gabriele Mora, Paolo Volanti, Maurizio Inghilleri and 9 more

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Ultrasonographic and manometric study of the tongue as biomarkers of dysphagia in patients with amyotrophic lateral sclerosis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 17 institutions in 3 countries.

Luca DiamantiIRCCS Mondino Foundation, Via Mondino 2, 27100, Pavia, Italy. luca.diamanti@mondino.it.ORCID http://orcid.org/0000-0002-4540-6886
Paola BorrelliLaboratory of Biostatistics, Department of Medical, Oral, and Biotechnological Sciences, University G. d'Annunzio Chieti-Pescara, Chieti, Italy.
Raffaele DubbiosoDepartment of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples Federico II, Naples, Italy.
Margherita CapassoNeurologic Clinic, SS. Annunziata Hospital, Chieti, Italy.
Claudia MorelliDepartment of Neurology and Laboratory of Neuroscience, Istituto Auxologico Italiano, IRCCS, Milan, Italy.
Christian LunettaNEMO Clinical Center, Serena Onlus Foundation, Milano, Italy.
Antonio PetrucciCenter for Neuromuscular and Neurological Rare Diseases, Neurology and Neurophysiology Unit, San Camillo Forlanini Hospital, Rome, Italy.
Gabriele MoraICS Maugeri IRCCS, Milano, Italy.
Paolo VolantiDepartment of Neurorehabilitation, Istituti Clinici Scientifici Maugeri IRCCS, Institute of Mistretta, Messina, Italy.
Maurizio InghilleriNeuromuscular Rare Disease Centre, Department Human Neurosciences, University of Rome La Sapienza, Rome, Italy.
Lucio TremolizzoNeurology, San Gerardo Hospital and University of Milano-Bicocca, Monza, Italy.
Jessica MandrioliDepartment of Biomedical, Metabolic and Neural Science, Center for Neuroscience and Neurotechnology, University of Modena and Reggio Emilia, Modena, Italy.
Letizia MazziniDepartment of Neurology and ALS Centre, University of Piemonte Orientale, Maggiore Della Carità Hospital, Novara, Italy.
Marcella VedovelloNeurology Unit, ASST Papa Giovanni XXIII, Bergamo, Italy.
Gabriele SicilianoCenter for Neuromuscular and Neurological Rare Diseases Neurological Clinic, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Massimiliano FilostoDepartment of Clinical and Experimental Sciences, University of Brescia, NeMO-Brescia Clinical Center for Neuromuscular Diseases, Brescia, Italy.
Sabrina MatàSOD Neurologia 1, Dipartimento Neuromuscolo-Scheletrico E Degli Organi Di Senso, Azienda Ospedaliero Universitaria Careggi, Florence, Italy.
Cristina MontomoliDepartment of Public Health, Experimental and Forensic Medicine, Unit of Biostatistics and Clinical Epidemiology, University of Pavia, Pavia, Italy.
DYALS Study Group
Istituti Clinici Scientifici Maugeri · ITAzienda Ospedaliero-Universitaria Careggi · ITCarlo Forlanini Hospital · ITCentro Clinico Nemo · ITFoundation Center · USIRCCS Istituto Auxologico Italiano · ITOspedale Papa Giovanni XXIII · ITOspedale SS. Annunziata · ITSapienza University of Rome · ITUniversità degli Studi del Piemonte Orientale “Amedeo Avogadro” · ITUniversity of Brescia · ITUniversity of Chieti-Pescara · ITUniversity of Milano-Bicocca · ITUniversity of Modena and Reggio Emilia · ITUniversity of Naples Federico II · ITUniversity of Pavia · ITUniversity of Pisa · IT

Funding

ministero della salute RC 2020-2021
6 · The paper itself

Abstract

backgroundDysphagia is a common symptom during the trajectory of ALS, and it can significantly impact on the quality of life and prognosis of patients. Nowadays, no specific tool for the screening of dysphagia in ALS is validated, and the approach is heterogeneous across the Italian centres.

objectiveTo validate the DYALS (dysphagia in amyotrophic lateral sclerosis) questionnaire, adapting the DYMUS (dysphagia in multiple sclerosis) questionnaire, for the assessment of dysphagia in ALS patients, in order to uniform the evaluations across the Italian ALS network.

methodsWe included 197 patients diagnosed with ALS following the El Escorial criteria, in sixteen Italian ALS centres between 1st December 2019 and 1st July 2020. For each patient, we collected clinical and demographic data and obtained ALSFRS-r score, ALSAQ-5 score, DYMUS score, and EAT-10 score.

resultsAcross the 197 patients, the ratio M/F was 113/84, and the median age was 64 years (IQR 56-72.5). Bulbar patients were 20%, and spinal patients 80%. The median ALSFRSr total score of patients was 35 (IQR 28-39). DYALS score was statistically higher in bulbar ALS than in spinal ALS (median = 6, IQR 4.5-9 vs median = 1, IQR 0-5, z = 6.253, p < 0.0001). DYALS questionnaire showed a high internal consistency (Cronbach's alpha = 0.88). There was a statistically significant correlation between DYALS and EAT-10 (rho = 0.90, p < 0.0001).

conclusionsDYALS scale is reliable, manageable, and easily usable for the screening of dysphagia in ALS. It can be shared with all the Italian ALS centres in order to collect uniform data for therapeutic strategies and clinical trials.

Indexed as

Amyotrophic Lateral SclerosisDeglutition DisordersMultiple SclerosisHumansMiddle AgedQuality of LifeSurveys and QuestionnairesALSDysphagiaScreening

Identifiers

PMID34853898
OpenAlexW3215083949

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.